BVF as of March 31, 2017
Portfolio Holdings for BVF
BVF holds 30 positions in its portfolio as reported in the March 2017 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Blueprint Medicines (BPMC) | 14.3 | $84M | 2.1M | 39.99 | |
| Chemocentryx | 9.9 | $58M | 8.0M | 7.28 | |
| Cytokinetics (CYTK) | 9.3 | $55M | 4.3M | 12.85 | |
| Anaptysbio Inc Common (ANAB) | 8.2 | $48M | 1.7M | 27.75 | |
| Concert Pharmaceuticals I equity | 6.8 | $40M | 2.3M | 17.06 | |
| Cytomx Therapeutics (CTMX) | 5.3 | $31M | 1.8M | 17.27 | |
| Forward Pharma A/s | 5.1 | $30M | 1.4M | 21.55 | |
| Infinity Pharmaceuticals (INFIQ) | 4.3 | $25M | 7.9M | 3.23 | |
| Array BioPharma | 4.2 | $25M | 2.8M | 8.94 | |
| Cti Biopharma | 3.2 | $19M | 4.5M | 4.20 | |
| Biolinerx Ltd-spons | 2.9 | $17M | 18M | 0.96 | |
| Oncomed Pharmaceuticals | 2.8 | $16M | 1.8M | 9.21 | |
| Glycomimetics | 2.6 | $15M | 2.8M | 5.43 | |
| Achillion Pharmaceuticals | 2.4 | $14M | 3.3M | 4.21 | |
| Loxo Oncology | 2.3 | $14M | 320k | 42.08 | |
| Cascadian Therapeutics | 2.2 | $13M | 3.1M | 4.14 | |
| Xenon Pharmaceuticals (XENE) | 2.0 | $12M | 2.9M | 4.00 | |
| Xoma Corp Del (XOMA) | 1.8 | $11M | 1.5M | 7.11 | |
| Fate Therapeutics (FATE) | 1.5 | $8.9M | 1.9M | 4.55 | |
| Immune Design | 1.4 | $8.4M | 1.2M | 6.80 | |
| ArQule | 1.3 | $7.8M | 7.4M | 1.06 | |
| Sunesis Pharmaceuticals Inc Ne | 1.1 | $6.3M | 1.5M | 4.10 | |
| Orexigen Therapeutics Inc. 144a 2 3/4% Due 12/1/2020 Jd1 note 2.750%12/0 | 0.9 | $5.5M | 10M | 0.55 | |
| Nivalis Therapeutics | 0.9 | $5.4M | 1.9M | 2.92 | |
| Gtx Inc Del | 0.9 | $5.4M | 1.1M | 4.86 | |
| Pieris Pharmaceuticals | 0.8 | $5.0M | 1.9M | 2.60 | |
| Anthera Pharmaceutcls | 0.6 | $3.5M | 8.1M | 0.43 | |
| Orexigen Therapeutics | 0.4 | $2.5M | 735k | 3.44 | |
| Pain Therapeutics | 0.3 | $2.0M | 2.3M | 0.89 | |
| Regulus Therapeutics | 0.2 | $1.0M | 623k | 1.65 |
